SCHEMBL4515675

SCHEMBL4515675

CCOC(=O)c1sc2nc(Cc3ccccc3OC(F)(F)F)[nH]c(=O)c2c1C

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 8/20 0.62
MEN1 O00255 6/20 0.62
ALDH1A1 P00352 7/20 0.61
L3MBTL1 Q9Y468 2/20 0.60
PIP4K2A P48426 1/20 0.55
TP53 P04637 1/20 0.54
MAPT P10636 4/20 0.53
PKM P14618 1/20 0.53
KDM4E B2RXH2 5/20 0.51
LMNA P02545 2/20 0.49
RXFP1 Q9HBX9 2/20 0.49
KCNH2 Q12809 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
GAA P10253 2/20 0.47
MAPK1 P28482 2/20 0.47
HPGD P15428 2/20 0.47
USP2 O75604 1/20 0.47
HSD17B10 Q99714 1/20 0.47
PDE9A O76083 1/20 0.47
PDE1A P54750 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4531543 0.89 KMT2A (0.65) KMT2AMEN1ALDH1A1L3MBTL1PIP4K2A
SCHEMBL3494970 0.89 ALDH1A1 (0.53) KMT2AMEN1ALDH1A1L3MBTL1MAPT
SCHEMBL4515763 0.89 KMT2A (0.65) KMT2AMEN1ALDH1A1L3MBTL1PIP4K2A
SCHEMBL4517005 0.88 KMT2A (0.64) KMT2AMEN1ALDH1A1L3MBTL1PIP4K2A
SCHEMBL4505315 0.86 KMT2A (0.72) KMT2AMEN1ALDH1A1L3MBTL1PIP4K2A
SCHEMBL4519184 0.86 KMT2A (0.68) KMT2AMEN1ALDH1A1L3MBTL1PIP4K2A
SCHEMBL4511752 0.85 KMT2A (0.62) KMT2AMEN1ALDH1A1L3MBTL1PIP4K2A
SCHEMBL4512139 0.85 KMT2A (0.66) KMT2AMEN1ALDH1A1L3MBTL1PIP4K2A
SCHEMBL4506234 0.84 KMT2A (0.76) KMT2AMEN1ALDH1A1L3MBTL1PIP4K2A
SCHEMBL4513728 0.84 KMT2A (0.61) KMT2AMEN1ALDH1A1L3MBTL1PIP4K2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1908765-B1 THIENOPYRIMIDINE DERIVATIVE ASKA PHARM CO LTD (JP) 2014-10-22 EP disclosed
US-8377944-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2013-02-19 US disclosed
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES GOTANDA KOTARO (JP) 2013-01-24 US disclosed
US-8293754-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-10-23 US disclosed
US-20090203703-A1 Thienopyrimidine Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-08-13 US disclosed
EP-1908765-A1 THIENOPYRIMIDINE DERIVATIVE ASKA Pharmaceutical Co., Ltd. (JP) 2008-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES PDE9A, BPHL, THOP1 KMT2A 2650/4885MEN1 2509/4885ALDH1A1 2303/4885
US-20090203703-A1 Thienopyrimidine Derivatives PDE9A, BPHL, THOP1 KMT2A 2650/4885MEN1 2509/4885ALDH1A1 2303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.